• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.

作者信息

Orlandi Ester M, Rocca Barbara, Pazzano Anna S, Ghio Stefano

出版信息

Leuk Res. 2012 Jan;36(1):e4-6. doi: 10.1016/j.leukres.2011.08.007. Epub 2011 Sep 3.

DOI:10.1016/j.leukres.2011.08.007
PMID:21890201
Abstract
摘要

相似文献

1
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.可逆性肺动脉高压可能与长期低剂量达沙替尼治疗慢性髓性白血病有关。
Leuk Res. 2012 Jan;36(1):e4-6. doi: 10.1016/j.leukres.2011.08.007. Epub 2011 Sep 3.
2
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.与达沙替尼治疗慢性粒细胞白血病相关的完全可逆性肺动脉高压。
Eur Respir J. 2011 Jul;38(1):218-20. doi: 10.1183/09031936.00154210.
3
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.一名慢性粒细胞白血病患者中继发于达沙替尼的可逆性重度肺动脉高压
Leuk Res. 2009 Jun;33(6):861-4. doi: 10.1016/j.leukres.2008.09.026. Epub 2008 Nov 4.
4
Reversible pre-capillary pulmonary hypertension due to dasatinib.达沙替尼所致的可逆性毛细血管前性肺动脉高压
Respir Care. 2014 May;59(5):e77-80. doi: 10.4187/respcare.02692. Epub 2013 Oct 22.
5
Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.达沙替尼诱发慢性粒细胞白血病患者的肺动脉高压
BMJ Case Rep. 2014 Apr 15;2014:bcr2014204477. doi: 10.1136/bcr-2014-204477.
6
[Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].[达沙替尼治疗慢性粒细胞白血病合并硬皮病患者导致的可逆性肺动脉高压]
Pol Merkur Lekarski. 2013 Jun;34(204):342-4.
7
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.达沙替尼用于伊马替尼耐药的费城染色体阳性白血病。
N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.
8
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.接受达沙替尼治疗的慢性髓性白血病患者出现的胸腔积液可能具有免疫介导的发病机制。
Br J Haematol. 2008 May;141(5):745-7. doi: 10.1111/j.1365-2141.2008.07108.x. Epub 2008 Mar 7.
9
Double-edged sword of the new cancer therapeutics.新型癌症治疗方法的双刃剑
Circulation. 2012 May 1;125(17):2057-8. doi: 10.1161/CIRCULATIONAHA.112.104844. Epub 2012 Mar 26.
10
[Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].[达沙替尼治疗慢性粒细胞白血病相关的可逆性肺动脉高压：一例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2014 Jul;35(7):581-6. doi: 10.3760/cma.j.issn.0253-2727.2014.07.002.

引用本文的文献

1
Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor - a pilot study.慢性骨髓增殖性疾病中毛细血管前性肺动脉高压的筛查：N 端前 B 型利钠肽和血管内皮生长因子的作用——一项初步研究
Arch Med Sci. 2020 Feb 27;17(6):1628-1635. doi: 10.5114/aoms.2020.93315. eCollection 2021.
2
A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.一篇关于达沙替尼不良反应的叙述性综述，重点关注达沙替尼诱导的肺部毒性的药物治疗。
Blood Res. 2021 Dec 31;56(4):229-242. doi: 10.5045/br.2021.2021117.
3
Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia.
右心室收缩压的变化可提示慢性髓性白血病中达沙替尼所致肺动脉高压。
Cancer Med. 2021 Mar;10(5):1515-1524. doi: 10.1002/cam4.3588. Epub 2021 Feb 15.
4
EXPRESS: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors.快报：达沙替尼及其他酪氨酸激酶抑制剂所致肺动脉高压
Pulm Circ. 2019 Jul 5;9(3):2045894019865704. doi: 10.1177/2045894019865704.
5
Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension.Rho激酶抑制改善达沙替尼诱导的内皮功能障碍和肺动脉高压。
Front Physiol. 2018 May 15;9:537. doi: 10.3389/fphys.2018.00537. eCollection 2018.
6
Dasatinib-induced pulmonary arterial hypertension.达沙替尼致肺动脉高压。
Br J Clin Pharmacol. 2018 May;84(5):835-845. doi: 10.1111/bcp.13508. Epub 2018 Mar 6.
7
Drug-induced pulmonary arterial hypertension: a review.药物性肺动脉高压：综述
Heart Fail Rev. 2017 May;22(3):289-297. doi: 10.1007/s10741-017-9612-9.
8
Hematological disorders and pulmonary hypertension.血液系统疾病与肺动脉高压。
World J Cardiol. 2016 Dec 26;8(12):703-718. doi: 10.4330/wjc.v8.i12.703.
9
Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension.二十二碳六烯酸通过 KCa 通道介导的超极化导致肺动脉高压中的肺动脉快速松弛。
Eur Respir J. 2016 Oct;48(4):1127-1136. doi: 10.1183/13993003.01814-2015. Epub 2016 Aug 18.
10
Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.第5组肺动脉高压：孤儿病中的孤儿病。
Cardiol Clin. 2016 Aug;34(3):443-9. doi: 10.1016/j.ccl.2016.04.004.